Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Artelo Biosciences was selected for its first-ever company presentation at BIO-Europe 2026, to be delivered by CSO Andrew Yates on November 10 in Cologne. The presentation will recap previously reported ART26.12 data, including favorable Phase 1 safety and pharmacokinetics and nonclinical efficacy in peripheral neuropathy and osteoarthritis models.
Key figures
- Event date
- November 9-11, 2026
- Presentation time
- 4:15pm CET on November 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.